[go: up one dir, main page]

MXPA03000188A - Metodo de tratamiento de enfermedades relacionadas con neutroficos con anestesicos locales. - Google Patents

Metodo de tratamiento de enfermedades relacionadas con neutroficos con anestesicos locales.

Info

Publication number
MXPA03000188A
MXPA03000188A MXPA03000188A MXPA03000188A MXPA03000188A MX PA03000188 A MXPA03000188 A MX PA03000188A MX PA03000188 A MXPA03000188 A MX PA03000188A MX PA03000188 A MXPA03000188 A MX PA03000188A MX PA03000188 A MXPA03000188 A MX PA03000188A
Authority
MX
Mexico
Prior art keywords
methods
related diseases
topical anesthetics
treating neutrophil
neutrophil
Prior art date
Application number
MXPA03000188A
Other languages
English (en)
Inventor
Loren W Hunt
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Publication of MXPA03000188A publication Critical patent/MXPA03000188A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MXPA03000188A 2000-06-23 2001-06-22 Metodo de tratamiento de enfermedades relacionadas con neutroficos con anestesicos locales. MXPA03000188A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21403100P 2000-06-23 2000-06-23
PCT/US2001/019977 WO2002000218A2 (en) 2000-06-23 2001-06-22 Methods of treating neutrophil-related diseases with topical anesthetics

Publications (1)

Publication Number Publication Date
MXPA03000188A true MXPA03000188A (es) 2003-09-22

Family

ID=22797503

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03000188A MXPA03000188A (es) 2000-06-23 2001-06-22 Metodo de tratamiento de enfermedades relacionadas con neutroficos con anestesicos locales.

Country Status (9)

Country Link
US (4) US6861449B2 (es)
EP (1) EP1296683A2 (es)
JP (1) JP2004501193A (es)
AU (2) AU2001271386B2 (es)
CA (1) CA2414389A1 (es)
IL (1) IL153574A0 (es)
MX (1) MXPA03000188A (es)
NO (1) NO20026222L (es)
WO (1) WO2002000218A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000188A (es) * 2000-06-23 2003-09-22 Mayo Foundation Metodo de tratamiento de enfermedades relacionadas con neutroficos con anestesicos locales.
US20040076671A1 (en) * 2002-10-21 2004-04-22 Aletha Tippett Methods and compositions for topical wound treatment
US6861499B2 (en) * 2003-02-24 2005-03-01 Triton Systems, Inc. Branched polyphosphonates that exhibit an advantageous combination of properties, and methods related thereto
WO2005060640A2 (en) * 2003-12-15 2005-07-07 Sarnoff Corporation Method and apparatus for object tracking prior to imminent collision detection
US7452524B2 (en) 2004-01-27 2008-11-18 Gilead Sciences, Inc. Method for improvement of tolerance for therapeutically effective agents delivered by inhalation
US7452523B2 (en) * 2004-01-27 2008-11-18 Gilead Sciences, Inc. Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks
AU2005310312A1 (en) * 2004-09-20 2006-06-08 Corus Pharma, Inc. A method for improvement of tolerance for therapeutically effective agents delivered by inhalation
AU2005290312A1 (en) * 2004-09-20 2006-04-06 Corus Pharma, Inc. Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks
AU2005316687B2 (en) * 2004-12-16 2008-06-26 Alkermes, Inc. Compositions and methods for pulmonary conditions
AU2006214384A1 (en) * 2005-02-14 2006-08-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of IL-17F in diagnosis and therapy of airway inflammation
CA2668652C (en) 2006-11-20 2018-06-12 President And Fellows Of Harvard College Inhibitors of voltage-gated ion channels for use in treating pain and pruritis
JP6205133B2 (ja) 2009-07-10 2017-09-27 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
JP6833811B2 (ja) 2015-08-03 2021-02-24 プレジデント アンド フェローズ オブ ハーバード カレッジ 荷電イオンチャネル遮断薬及び使用方法
CN113811305A (zh) 2019-03-11 2021-12-17 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法
SG11202109713PA (en) 2019-03-11 2021-10-28 Nocion Therapeutics Inc Ester substituted ion channel blockers and methods for use
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
IL286172B1 (en) 2019-03-11 2025-10-01 Nocion Therapeutics Inc Charged ion channel blockers and methods of use
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CA3155568A1 (en) 2019-11-06 2021-05-14 Bridget Mccarthy Cole Charged ion channel blockers and methods for use
IL292505A (en) 2019-11-06 2022-06-01 Nocion Therapeutics Inc Charged ion channel blockers and methods of use
WO2021183639A1 (en) 2020-03-11 2021-09-16 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US12162851B2 (en) 2020-03-11 2024-12-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
NL2025253B1 (en) * 2020-03-31 2021-10-22 Hasan Djohan Use of lidocaine in treatment of respiratory diseases
PL4125843T3 (pl) * 2020-03-31 2025-09-22 Remicine IP B.V. Leczenie ciężkiego zespołu zapalnego
US20210346625A1 (en) * 2020-05-07 2021-11-11 West Virginia University Board of Governors on behalf of West Virginia University Methods of improving autonomic imbalance or sympathetic impairment by regulating the stellate ganglion
CN113764038B (zh) * 2021-08-31 2023-08-22 华南理工大学 构建骨髓增生异常综合征转白基因预测模型的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103302D0 (en) * 1991-02-16 1991-04-03 Smithkline Beecham Plc Pharmaceutical formulations
US5510339A (en) * 1993-02-02 1996-04-23 Mayo Foundation For Medical Education And Research Method for the treatment of bronchial asthma by administration of topical anesthetics
US6362197B1 (en) * 1998-06-09 2002-03-26 Cardiome Pharma Corp. Compositions and method for treatment of cough
MXPA03000188A (es) * 2000-06-23 2003-09-22 Mayo Foundation Metodo de tratamiento de enfermedades relacionadas con neutroficos con anestesicos locales.

Also Published As

Publication number Publication date
AU7138601A (en) 2002-01-08
US20040077717A1 (en) 2004-04-22
US6861449B2 (en) 2005-03-01
AU2001271386B2 (en) 2005-04-07
WO2002000218A2 (en) 2002-01-03
US20060100276A1 (en) 2006-05-11
EP1296683A2 (en) 2003-04-02
JP2004501193A (ja) 2004-01-15
WO2002000218A3 (en) 2002-05-16
US20030171402A1 (en) 2003-09-11
CA2414389A1 (en) 2002-01-03
US20090054485A1 (en) 2009-02-26
IL153574A0 (en) 2003-07-06
NO20026222L (no) 2003-02-20
US7816374B2 (en) 2010-10-19
NO20026222D0 (no) 2002-12-23

Similar Documents

Publication Publication Date Title
MXPA03000188A (es) Metodo de tratamiento de enfermedades relacionadas con neutroficos con anestesicos locales.
IL162533A0 (en) Chalcone derivatives and their use to treat diseases
AU2002231039A1 (en) Therapeutic stockings
AU2001282717A1 (en) Cancer treatment by combination therapy
MXPA03002813A (es) Compuestos utiles en el tratamiento de enfermedades inflamatorias.
GB0028264D0 (en) Well treatment
AU2002343739A1 (en) Improved therapy for topical diseases
GB0028269D0 (en) Well treatment
GB0028429D0 (en) Therapy
AUPQ877300A0 (en) Topical treatment of skin
AU2000258352A1 (en) Acupuncture points stimulation for treating various diseases
MXPA03008634A (es) Nuevos compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
PL354110A1 (en) Combined therapy for treating the both alcoholism and alcohol dependence
GB0004531D0 (en) The treatment of respiratory diseases
AU2001227972A1 (en) Methods to treat alpha-1-antitrypsin deficiency
AU2001232787A1 (en) Airway alkalinization as therapy for airway diseases
AU2001251306A1 (en) Treatment of sleep disorders with hypocretin-1
GB0001710D0 (en) Therapeutic treatment
HRP20020729A2 (en) Treatment of psoriasis
HUP0300222A3 (en) Novel lhrh-antagonists, production and use thereof as medicament
AU2002216758A1 (en) Quinazolines with therapeutic use
AU2096002A (en) Therapeutic treatment
AU2001261324A1 (en) Psoriasis treatment
ZA200205415B (en) Novel therapeutic use of enoxaparin.
AU2001289127A1 (en) Tumor treatment